BioLineRx (BLRX) Total Non-Current Liabilities (2023 - 2025)
Historic Total Non-Current Liabilities for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $6.6 million.
- BioLineRx's Total Non-Current Liabilities fell 6574.84% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year decrease of 6574.84%. This contributed to the annual value of $10.0 million for FY2024, which is 2678.71% up from last year.
- Latest data reveals that BioLineRx reported Total Non-Current Liabilities of $6.6 million as of Q3 2025, which was down 6574.84% from $7.7 million recorded in Q2 2025.
- In the past 5 years, BioLineRx's Total Non-Current Liabilities registered a high of $25.4 million during Q2 2023, and its lowest value of $6.6 million during Q3 2025.
- Over the past 3 years, BioLineRx's median Total Non-Current Liabilities value was $10.0 million (recorded in 2024), while the average stood at $14.1 million.
- In the last 5 years, BioLineRx's Total Non-Current Liabilities soared by 2678.71% in 2024 and then tumbled by 6574.84% in 2025.
- Over the past 3 years, BioLineRx's Total Non-Current Liabilities (Quarter) stood at $7.9 million in 2023, then increased by 26.79% to $10.0 million in 2024, then tumbled by 34.24% to $6.6 million in 2025.
- Its Total Non-Current Liabilities stands at $6.6 million for Q3 2025, versus $7.7 million for Q2 2025 and $8.6 million for Q1 2025.